Yazar "Turk, Haci Mehmet" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Opinions of the Turkish population on cancer and being informed of the diagnosis of cancer
    (Tubitak Scientific & Technological Research Council Turkey, 2015) Yalcin, Abdussamed; Silay, Kamile; Buyukcelik, Abdullah; Isikdogan, Abdurrahman; Turk, Haci Mehmet; Coskun, Hasan Senol; Ozdemir, Feyyaz
    Background/aim: An opinion survey was conducted to investigate the opinions and attitudes of the Turkish population regarding cancer if they or one of their family members were to receive a diagnosis of cancer. Materials and methods: The opinion survey was completed by 6566 subjects and consisted of questions about the demographics of the participants and their overall opinions about cancer. The other points of the investigation asked whether they would inform relatives who had cancer about the diagnosis and whether they would prefer to be informed if they were the one with the cancer diagnosis. Results: The median age of the participants was 33 years (range: 18-100) and 53.3% were male. It was found that 57.7% of the participants would prefer not to disclose a cancer diagnosis to their first-degree relatives. The diagnosis had been disclosed to relatives with cancer in 69.9% of cases. When asked about their overall opinion of cancer management, 76.5% of participants were optimistic, 16.3% were pessimistic, and 2.9% had mixed opinions. Conclusion: This study represents one of the largest surveys done in Turkey to identify the thoughts of healthy people about cancer and their opinion on informing their relatives about the diagnosis if the relatives have cancer. It is comparable with reports from East Europe and Asian countries.
  • [ X ]
    Öğe
    Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
    (Sage Publications Ltd, 2024) Yildirim, Mahmut Emre; Karadurmus, Nuri; Okten, Ilker Nihat; Turk, Haci Mehmet; Urakci, Zuhat; Arslan, Cagatay; Celik, Sinemis
    Backgrounds and Objectives Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311).Materials and Methods In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups.Results A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively (p = 0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively (p = 0.848).Conclusion According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.